2,3′,4,5′-Tetramethoxystilbene prevents deoxycorticosterone- salt-induced hypertension: Contribution of cytochrome P-450 1B1

Seyhan Sahan-Firat, Brett L. Jennings, Fariborz A. Yaghini, Chi Young Song, Anne M. Estes, Xiao R. Fang, Nasreen Farjana, Amir I. Khan, Kafait Malik

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Reactive oxygen species (ROS) contribute to various models of hypertension, including deoxycorticosterone acetate (DOCA)-salt-induced hypertension. Recently, we have shown that ROS, generated by cytochrome P-450 1B1 (CYP1B1) from arachidonic acid, mediate vascular smooth muscle cell growth caused by angiotensin II. This study was conducted to determine the contribution of CYP1B1 to hypertension and associated pathophysiological changes produced by DOCA (30 mg/kg) given subcutaneously per week with 1% NaCl + 0.1% KCl in drinking water to uninephrectomized rats for 6 wk. DOCA-salt treatment increased systolic blood pressure (SBP). Injections of the selective inhibitor of CYP1B1, 2,3′,4,5′-tetramethoxystilbene (TMS; 300 μg/kg ip every 3rd day) initiated at the 4th week of DOCA-salt treatment normalized SBP and decreased CYP1B1 activity but not its expression in the aorta, heart, and kidney. TMS also inhibited cardiovascular and kidney hypertrophy, prevented the increase in vascular reactivity and endothelial dysfunction, and minimized the increase in urinary protein and K+ output and the decrease in urine osmolality, Na+ output, and creatinine clearance associated with DOCA-salt treatment. These pathophysiological changes caused by DOCA-salt treatment and associated increase in vascular superoxide production, NADPH oxidase activity, and expression of NOX-1, and ERK1/2 and p38 MAPK activities in the aorta, heart, and kidney were inhibited by TMS. These data suggest that CYP1B1 contributes to DOCA-salt-induced hypertension and associated pathophysiological changes, most likely as a result of increased ROS production and ERK1/2 and p38 MAPK activity, and could serve as a novel target for the development of agents like TMS to treat hypertension.

Original languageEnglish (US)
JournalAmerican Journal of Physiology - Heart and Circulatory Physiology
Volume299
Issue number6
DOIs
StatePublished - Dec 1 2010

Fingerprint

Desoxycorticosterone
Cytochrome P-450 Enzyme System
Acetates
Salts
Hypertension
Blood Pressure
Reactive Oxygen Species
p38 Mitogen-Activated Protein Kinases
Kidney
Blood Vessels
Aorta
NADPH Oxidase
Therapeutics
Vascular Smooth Muscle
Arachidonic Acid
Superoxides
Angiotensin II
Drinking Water
Osmolar Concentration
Hypertrophy

All Science Journal Classification (ASJC) codes

  • Physiology
  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this

2,3′,4,5′-Tetramethoxystilbene prevents deoxycorticosterone- salt-induced hypertension : Contribution of cytochrome P-450 1B1. / Sahan-Firat, Seyhan; Jennings, Brett L.; Yaghini, Fariborz A.; Song, Chi Young; Estes, Anne M.; Fang, Xiao R.; Farjana, Nasreen; Khan, Amir I.; Malik, Kafait.

In: American Journal of Physiology - Heart and Circulatory Physiology, Vol. 299, No. 6, 01.12.2010.

Research output: Contribution to journalArticle

Sahan-Firat, Seyhan ; Jennings, Brett L. ; Yaghini, Fariborz A. ; Song, Chi Young ; Estes, Anne M. ; Fang, Xiao R. ; Farjana, Nasreen ; Khan, Amir I. ; Malik, Kafait. / 2,3′,4,5′-Tetramethoxystilbene prevents deoxycorticosterone- salt-induced hypertension : Contribution of cytochrome P-450 1B1. In: American Journal of Physiology - Heart and Circulatory Physiology. 2010 ; Vol. 299, No. 6.
@article{307bcca869e84579a3d859025081cb3d,
title = "2,3′,4,5′-Tetramethoxystilbene prevents deoxycorticosterone- salt-induced hypertension: Contribution of cytochrome P-450 1B1",
abstract = "Reactive oxygen species (ROS) contribute to various models of hypertension, including deoxycorticosterone acetate (DOCA)-salt-induced hypertension. Recently, we have shown that ROS, generated by cytochrome P-450 1B1 (CYP1B1) from arachidonic acid, mediate vascular smooth muscle cell growth caused by angiotensin II. This study was conducted to determine the contribution of CYP1B1 to hypertension and associated pathophysiological changes produced by DOCA (30 mg/kg) given subcutaneously per week with 1{\%} NaCl + 0.1{\%} KCl in drinking water to uninephrectomized rats for 6 wk. DOCA-salt treatment increased systolic blood pressure (SBP). Injections of the selective inhibitor of CYP1B1, 2,3′,4,5′-tetramethoxystilbene (TMS; 300 μg/kg ip every 3rd day) initiated at the 4th week of DOCA-salt treatment normalized SBP and decreased CYP1B1 activity but not its expression in the aorta, heart, and kidney. TMS also inhibited cardiovascular and kidney hypertrophy, prevented the increase in vascular reactivity and endothelial dysfunction, and minimized the increase in urinary protein and K+ output and the decrease in urine osmolality, Na+ output, and creatinine clearance associated with DOCA-salt treatment. These pathophysiological changes caused by DOCA-salt treatment and associated increase in vascular superoxide production, NADPH oxidase activity, and expression of NOX-1, and ERK1/2 and p38 MAPK activities in the aorta, heart, and kidney were inhibited by TMS. These data suggest that CYP1B1 contributes to DOCA-salt-induced hypertension and associated pathophysiological changes, most likely as a result of increased ROS production and ERK1/2 and p38 MAPK activity, and could serve as a novel target for the development of agents like TMS to treat hypertension.",
author = "Seyhan Sahan-Firat and Jennings, {Brett L.} and Yaghini, {Fariborz A.} and Song, {Chi Young} and Estes, {Anne M.} and Fang, {Xiao R.} and Nasreen Farjana and Khan, {Amir I.} and Kafait Malik",
year = "2010",
month = "12",
day = "1",
doi = "10.1152/ajpheart.00655.2010",
language = "English (US)",
volume = "299",
journal = "American Journal of Physiology",
issn = "0363-6135",
publisher = "American Physiological Society",
number = "6",

}

TY - JOUR

T1 - 2,3′,4,5′-Tetramethoxystilbene prevents deoxycorticosterone- salt-induced hypertension

T2 - Contribution of cytochrome P-450 1B1

AU - Sahan-Firat, Seyhan

AU - Jennings, Brett L.

AU - Yaghini, Fariborz A.

AU - Song, Chi Young

AU - Estes, Anne M.

AU - Fang, Xiao R.

AU - Farjana, Nasreen

AU - Khan, Amir I.

AU - Malik, Kafait

PY - 2010/12/1

Y1 - 2010/12/1

N2 - Reactive oxygen species (ROS) contribute to various models of hypertension, including deoxycorticosterone acetate (DOCA)-salt-induced hypertension. Recently, we have shown that ROS, generated by cytochrome P-450 1B1 (CYP1B1) from arachidonic acid, mediate vascular smooth muscle cell growth caused by angiotensin II. This study was conducted to determine the contribution of CYP1B1 to hypertension and associated pathophysiological changes produced by DOCA (30 mg/kg) given subcutaneously per week with 1% NaCl + 0.1% KCl in drinking water to uninephrectomized rats for 6 wk. DOCA-salt treatment increased systolic blood pressure (SBP). Injections of the selective inhibitor of CYP1B1, 2,3′,4,5′-tetramethoxystilbene (TMS; 300 μg/kg ip every 3rd day) initiated at the 4th week of DOCA-salt treatment normalized SBP and decreased CYP1B1 activity but not its expression in the aorta, heart, and kidney. TMS also inhibited cardiovascular and kidney hypertrophy, prevented the increase in vascular reactivity and endothelial dysfunction, and minimized the increase in urinary protein and K+ output and the decrease in urine osmolality, Na+ output, and creatinine clearance associated with DOCA-salt treatment. These pathophysiological changes caused by DOCA-salt treatment and associated increase in vascular superoxide production, NADPH oxidase activity, and expression of NOX-1, and ERK1/2 and p38 MAPK activities in the aorta, heart, and kidney were inhibited by TMS. These data suggest that CYP1B1 contributes to DOCA-salt-induced hypertension and associated pathophysiological changes, most likely as a result of increased ROS production and ERK1/2 and p38 MAPK activity, and could serve as a novel target for the development of agents like TMS to treat hypertension.

AB - Reactive oxygen species (ROS) contribute to various models of hypertension, including deoxycorticosterone acetate (DOCA)-salt-induced hypertension. Recently, we have shown that ROS, generated by cytochrome P-450 1B1 (CYP1B1) from arachidonic acid, mediate vascular smooth muscle cell growth caused by angiotensin II. This study was conducted to determine the contribution of CYP1B1 to hypertension and associated pathophysiological changes produced by DOCA (30 mg/kg) given subcutaneously per week with 1% NaCl + 0.1% KCl in drinking water to uninephrectomized rats for 6 wk. DOCA-salt treatment increased systolic blood pressure (SBP). Injections of the selective inhibitor of CYP1B1, 2,3′,4,5′-tetramethoxystilbene (TMS; 300 μg/kg ip every 3rd day) initiated at the 4th week of DOCA-salt treatment normalized SBP and decreased CYP1B1 activity but not its expression in the aorta, heart, and kidney. TMS also inhibited cardiovascular and kidney hypertrophy, prevented the increase in vascular reactivity and endothelial dysfunction, and minimized the increase in urinary protein and K+ output and the decrease in urine osmolality, Na+ output, and creatinine clearance associated with DOCA-salt treatment. These pathophysiological changes caused by DOCA-salt treatment and associated increase in vascular superoxide production, NADPH oxidase activity, and expression of NOX-1, and ERK1/2 and p38 MAPK activities in the aorta, heart, and kidney were inhibited by TMS. These data suggest that CYP1B1 contributes to DOCA-salt-induced hypertension and associated pathophysiological changes, most likely as a result of increased ROS production and ERK1/2 and p38 MAPK activity, and could serve as a novel target for the development of agents like TMS to treat hypertension.

UR - http://www.scopus.com/inward/record.url?scp=78649731418&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649731418&partnerID=8YFLogxK

U2 - 10.1152/ajpheart.00655.2010

DO - 10.1152/ajpheart.00655.2010

M3 - Article

C2 - 20852048

AN - SCOPUS:78649731418

VL - 299

JO - American Journal of Physiology

JF - American Journal of Physiology

SN - 0363-6135

IS - 6

ER -